Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|December 13, 2007

Filtration System

Sartorius Stedim Biotech has developed SARTOFLOW Alpha plus, a flexible modular benchtop crossflow filtration system, which provides semi-automatic micro-, ultra-, and diafiltration, and is especially suited for process development, clinical testing, and smaller production processes.

Sartorius Stedim Biotech has developed SARTOFLOW Alpha plus, a flexible modular benchtop crossflow filtration system, which provides semi-automatic micro-, ultra-, and diafiltration, and is especially suited for process development, clinical testing, and smaller production processes. Because of its standardized options, the system can be adapted to the changing production demands of downstream processing. The steaming-in-place module for thermal sterilization gives users the option to run all cross flow processes aseptically. The SARTOFLOW Alpha plus system is cGMP-compliant and self-draining. The system operates with either disposable bag technology or permanently installed tank. The cross-flow system is equipped with a DCU4 control module, which allows communication with the SCADA MFCS/WIN data logging and control software from Sartorius Stedim Biotech and makes integration with existing networks effortless.
www.sartorius-stedim.com.


Related to this article

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.